Literature DB >> 26579698

Patients with obesity-related comorbidities have higher disability compared with those without obesity-related comorbidities: results from a cross-sectional study.

Anna Sirtori1, Amelia Brunani, Paolo Capodaglio, Maria E Berselli, Valentina Villa, Francesca Ceriani, Stefania Corti, Matilde Leonardi, Alberto Raggi.   

Abstract

The aim of the present study was to describe disability in adult obese patients with obesity-related comorbidities, and to compare it with that of patients without obesity-related comorbidities. Two groups of obese patients were administered a set of 166 International Classification of Functioning, Disability and Health (ICF) categories; on the basis of this set, count-based indexes were developed for each ICF component and difference between patients with and without comorbidities were assessed with independent-sample t-test and Cohen's d as a measure of effect size. ICF categories in which at least 20% of patients reported a problem were considered relevant for describing functioning of obese patients; for each of them, the risk of having obesity-related comorbidities was calculated using odds ratio and 95% confidence interval. A total of 106 inpatients were enrolled in the study: 68 ICF categories reached the 20% threshold, and 31 of them were relevant only among patients with comorbidities. The presence of obesity-related comorbidities was associated with an increased risk of bodily impairments and limitations in performing daily activities. Compared with patients without obesity-related comorbidities, those with comorbidities showed higher disability. Comorbidities contribute to obesity-related disability, and our results support the importance of early rehabilitation interventions to reduce disability.

Entities:  

Mesh:

Year:  2016        PMID: 26579698     DOI: 10.1097/MRR.0000000000000146

Source DB:  PubMed          Journal:  Int J Rehabil Res        ISSN: 0342-5282            Impact factor:   1.479


  5 in total

1.  Defining the appropriate setting for treating obese patients: do we have the right tools?

Authors:  Luisella Vigna; Amelia Brunani; Gianna Maria Agnelli; Maria Rosaria Ingenito; Silvia Tomaino; Dario Consonni; Paolo Capodaglio; Lorenzo Maria Donini
Journal:  Eat Weight Disord       Date:  2018-10-24       Impact factor: 4.652

2.  A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.

Authors:  Maria J Pereira; Per Lundkvist; Prasad G Kamble; Joey Lau; Julian G Martins; C David Sjöström; Volker Schnecke; Anna Walentinsson; Eva Johnsson; Jan W Eriksson
Journal:  Diabetes Ther       Date:  2018-06-13       Impact factor: 2.945

3.  Investigating the Role of Myeloperoxidase and Angiopoietin-like Protein 6 in Obesity and Diabetes.

Authors:  Mohammad G Qaddoumi; Muath Alanbaei; Maha M Hammad; Irina Al Khairi; Preethi Cherian; Arshad Channanath; Thangavel Alphonse Thanaraj; Fahd Al-Mulla; Mohamed Abu-Farha; Jehad Abubaker
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

4.  Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis.

Authors:  Yun Kyung Cho; Ye-Jee Kim; Chang Hee Jung
Journal:  J Obes Metab Syndr       Date:  2021-12-30

Review 5.  Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.

Authors:  Maria J Pereira; Jan W Eriksson
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.